摘要
男性前列腺癌在发达国家中是非常普遍的,但检测癌症的显著比例保持惰性,没有成为强劲的癌。这凸显了需要改进可以区分懒惰的和有潜在危险的情况之间的生物标志物。前列腺特异性G蛋白偶联受体(PSGR 或者OR51E2)是一个在人类前列腺上皮细胞特异性高表达嗅觉受体家族成员,它高表达于PIN和前列腺癌。前列腺特异性G蛋白偶联受体已经参与了前列腺癌细胞的侵袭性,提示在转移性前列腺癌的转移的潜在作用。最近,转基因小鼠过度表达的前列腺特异性G蛋白偶联受体在前列腺报告制定急性炎症反应,其次是低级PIN出现,而前列腺特异性G蛋白偶联受体的小鼠过度表达PTEN的缺失具有侵袭性前列腺癌的小鼠加速形成。本文将总结最近的对前列腺特异性G蛋白偶联受作为一个潜在的前列腺癌生物标志物和前列腺癌的侵袭和炎症调节作用的焦点体的角色。
关键词: 肿瘤标志物,G蛋白偶联受体,炎症浸润,嗅觉受体,前列腺特异性G蛋白偶联受体,前列腺癌。
Current Molecular Medicine
Title:Prostate-Specific G-Protein Coupled Receptor, an Emerging Biomarker Regulating Inflammation and Prostate Cancer Invasion
Volume: 16 Issue: 6
Author(s): M. Rodriguez, S. Siwko, M. Liu
Affiliation:
关键词: 肿瘤标志物,G蛋白偶联受体,炎症浸润,嗅觉受体,前列腺特异性G蛋白偶联受体,前列腺癌。
摘要: Prostate cancer is highly prevalent among men in developed countries, but a significant proportion of detected cancers remain indolent, never progressing into aggressive carcinomas. This highlights the need to develop refined biomarkers that can distinguish between indolent and potentially dangerous cases. The prostate-specific G-protein coupled receptor (PSGR, or OR51E2) is an olfactory receptor family member with highly specific expression in human prostate epithelium that is highly overexpressed in PIN and prostate cancer. PSGR has been functionally implicated in prostate cancer cell invasiveness, suggesting a potential role in the transition to metastatic PCa. Recently, transgenic mice overexpressing PSGR in the prostate were reported to develop an acute inflammatory response followed by emergence of low grade PIN, whereas mice with compound PSGR overexpression and loss of PTEN exhibited accelerated formation of invasive prostate adenocarcinoma. This article will review recent PSGR findings with a focus on its role as a potential prostate cancer biomarker and regulator of prostate cancer invasion and inflammation.
Export Options
About this article
Cite this article as:
M. Rodriguez, S. Siwko, M. Liu , Prostate-Specific G-Protein Coupled Receptor, an Emerging Biomarker Regulating Inflammation and Prostate Cancer Invasion, Current Molecular Medicine 2016; 16 (6) . https://dx.doi.org/10.2174/1566524016666160607091333
DOI https://dx.doi.org/10.2174/1566524016666160607091333 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Targets, New Agents, and the Evolving Phenomena of Drug Resistance in Cancer
Current Cancer Therapy Reviews Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Review of Noscapine and its Analogues as Potential Anti-Cancer Drugs
Mini-Reviews in Organic Chemistry Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Density Functional Theory, Docking, Bioisosteric Replacement, Pharmacophore Perception, Physical Chemical Analyses of the Interactions of Novel PIM-1 Inhibitors with Suitable Pharmacokinetic Properties for Cancer Treatment
Current Physical Chemistry NSAIDs Induced Regulation of Alternatively Spliced Transcript Isoforms: Possible Role in Cancer and Alzheimer Disease
Current Cancer Drug Targets Dietary Small Molecules and Large-Scale Gene Expression Studies: An Experimental Approach for Understanding their Beneficial Effects on the Development of Malignant and Non-Malignant Proliferative Diseases
Current Medicinal Chemistry A Review of Animal and Human Studies for Management of Benign Prostatic Hyperplasia with Natural Products: Perspective of New Pharmacological Agents
Inflammation & Allergy - Drug Targets (Discontinued) Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
Current Cancer Drug Targets Hormonal Contraception in Men
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology The DREAM of Pain Relief
Current Rheumatology Reviews Network-based Assessment on Chemical-induced Cholestatic Liver Injury
Current Topics in Medicinal Chemistry Nanoparticles for Targeting of Prostate Cancer
Current Pharmaceutical Design Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets Introduction: MMPs, ADAMs/ADAMTSs Research Products to Achieve Big Dream
Anti-Cancer Agents in Medicinal Chemistry Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Ipilimumab Targeting CD28-CTLA-4 Axis: New Hope in the Treatment of Melanoma
Current Topics in Medicinal Chemistry Nanoprobes for Medical Diagnosis: Current Status of Nanotechnology in Molecular Imaging
Current Nanoscience Kinase Inhibitors in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry